N/A N=97 The Impact of Distress on the IVF Outcome
Infertility
Primary: Clinical Pregnancy Rates — 20; 52 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer
Chemotherapy-induced Neutropenia
Primary: CTCAE Grade 3/4 Neutropenia Incidence — 18; 13; 11 participants — p=<0.05
Phase 3 N=60 Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease
Meniere's Disease
Primary: Vertigo Attacks — 16.4; 19.93; 1.6; 2.5 Vertigo Attacks — p=0.271
Phase 2 N=55 FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Malignant Pleural Effusion · Stage IIIB Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Overall Response Rate (Patients That Achieve a CR or PR) — 13 participants
N/A N=17 TMS Treatment for Pain in Chronic Pancreatitis
Idiopathic Chronic Pancreatitis · Pain
Primary: Pain (Visual Analog Scale, CGI, PGA) — 7; 0 number of participants w/ reduced pain
Phase 2 N=97 Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
Lung Cancer
Primary: Overall Survival (12-month Rate Reported) — 60.1; 50.8 percentage of participants — p=0.2103
Phase 4 N=38 Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy
Diabetes · Atherosclerosis
Primary: Brachial Artery Flow Mediated Dilation — 5.2; 5.6; 5.6; 6.3 %FMD — p=<0.05
N/A N=472 Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).
Gastrointestinal Stromal Tumors
Primary: Number of Participants With Treatment-Related Adverse Events — 450 Participants
Phase 2 N=25 Montelukast to Treat Bronchiolitis Obliterans
Bronchiolitis Obliterans · Chronic Graft Versus Host Disease · Leukotriene
Primary: Number of Participants With Stable or Improved Predicted Forced Expiratory Volume 1 (FEV-1) With Published Literature — 5; 7; 6; 1 Participants
Phase 2 N=86 Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol
Cardiovascular Disease
Primary: Total Serum Cholesterol Levels for Alpha-cyclodextrin (a-CD) and Placebo Groups After 12-14 Weeks, Compared to Baseline — 180; 180 mg/dL — p=0.82
Phase 1 N=146 A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults
Respiratory Syncytial Virus (RSV)
Primary: Number of Participants With Solicited Symptoms — 6; 4; 15; 7 participants
N/A N=1,015 CoreValve Advance International Post Market Study
Severe Aortic Stenosis
Primary: Major Adverse Cardiac & Cerebrovascular Events (MACCE) — 92 Freedom from MACCE (%) @30days
Phase 3 N=12 A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis
Psoriasis
Primary: Time to at Least a 1 Point Improvement on the Patient's Global Assessment of Disease Severity (PatGA) Score — 5.0; 6.0 Days
N/A N=211 Liposomal Bupivacaine Versus Standard Analgesia in Total Joint Arthroplasty (TJA)
Osteoarthritis, Knee · Osteoarthritis, Hip · Osteoarthritis, Shoulder
Primary: Length of Stay in Hospital (Days) — 2.0; 2.0 days — p=0.764
N/A N=46 Intelligent Pain Management System for Assessing Pain in Cancer Patients
Pain · Neoplasms
Primary: Feasibility of Mobile Application Assessed by Observing the Number of Daily Pain Assessments Recorded Among Patients — 2.37 pain assessments per day